LLOYD HATTON: Open Payments
NPI 1972138170 · SHERMAN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,073 in 117 payments from 15 companies in 2025. Trend: 2023 $2,523 · 2024 $1,915 · 2025 $2,073
Food & beverage: $2,073
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 21 | $353 |
| Lundbeck LLC | 13 | $250 |
| Vanda Pharmaceuticals Inc. | 13 | $231 |
| Teva Pharmaceuticals USA, Inc. | 13 | $228 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $225 |
| ABBVIE INC. | 14 | $187 |
| Neurocrine BioSciences, Inc. | 10 | $168 |
| Janssen Pharmaceuticals, Inc | 7 | $152 |
| Axsome Therapeutics, Inc. | 4 | $72 |
| E.R. Squibb & Sons, L.L.C. | 4 | $70 |
Products named: REXULTI, FANAPT, CAPLYTA, VRAYLAR, INGREZZA, AUSTEDO XR, INVEGA SUSTENNA, UZEDY.
Industry payments across TX — which companies pay providers there.
